2008-12-08-世界卫生组织-INN_Proposed_List_100_57页_497kb

Here is a summary of the proposed INN list 100 from the provided text:

• Blinatumumabum: Monoclonal antibody targeting CD19 and CD3, used for antineoplastic therapy.
• Adarotenum: Antineoplastic agent, a synthetic organic compound.
• Afamelanotum: Melanocortine receptor agonist, classified as an antineoplastic drug.
• Alisporivirum: Antiviral peptide with cyclosporine structure.
• Amenamevirum: Another antiviral, a synthetic chemical compound.
• Atigliflozinum: Structured to enhance antihyperglycaemic effects.
• Balapiravirum: Antiviral cyclic nucleotide analogue.
• Beloranibum: Antineoplastic agent described by a complex molecule.
• Canosimibum: Neuroprotective agent with clinched name structure mentioned around line 314-320.
• Cixutumumabum: Antibody against IGF-1R, a key signalling pathway in cancers.
• Coleneuramidum: Neuroprotective agent; name structure indicated at page 317-318.
• Cositecanum: Part of INN list 97 amendment; antineoplastic drug.
• Cutamesinum:sigma receptor ligand, potential analgesic or therapeutic agent.
• Davunetidum: Previously proposed as neuroprotective agent (now superseded).
• Fosbretabulinum: Part of INN list 95 amendment; antineoplastic drug originally targeting cell death receptor pathways.
• Fostamatinibum: Tyrosine kinase inhibitor for antineoplastic use.
• Hidrogenetinum: Indicated at page 325-326 as progestogen functions were handled in gest prefixed name; refers to synthetically produced progestogen.
• Indeglitazarum: Antihyperglycaemic agent, a substituted pyrimidine carboxylic acid.
• Ingenoli mebutatum: Antineoplastic topoisomerase inhibitor.
• Laninamivirum: Antiviral, synthetic analogue of known M2 antagonist. (Page 324-326 might be a typo, should be ingenol; INN for Japanese encephalitis treatment)
• Lesogaberanum: GABA receptor agonist; structurally similar to GHB.
• Lotilibcinum: Part of INN list 96 amendment; antibiotic investigated.
• Macimorelinum: Growth hormone release stimulating peptide used in diagnostics.
• Namitecanum: Part of INN List 99 amendment; antineoplastic agent.
• Neцитумум (corrected spelling: Necitumumabum): Epidermal growth factor receptor targeting antibody.
• Oportuzumabum: Coupled antibody-toxin construct for antineoplastic therapy.
• Panobacumabum: Bivalent antibody format against Pseudomonas aeruginosa.
• Pozaniclinum: Partial agonist at the nicotinic acetylcholine receptor; used in smoking cessation.
• Ramucirumabum: Antibody against VEGFR2, used in cancer therapy.
• Solanezumabum: Monoclonal antibody targeting amyloid-beta in Alzheimer's disease.
• **Tabelemumum (appears typo for tabetumumab): Recombinant viral vector therapy for cardiovascular restenosis.
• Telcecagpantum: Specifically designed to block P2X7 purinoceptor for migraine treatment: Inhibit P2X7R, Neuroprotection indication.
• Tilivapramum: Inhibits phosphodiesterase IV (PDE4), used in anti-inflammation/inflammation control.
• Tocranibum: Neoplastic agent designed to block FLT3 and PDGFR pathways.
• Torelasinum/Tozasertibum: Targets FLT3 tyrosine kinase receptor, used in cancers.
• Vedolizumabum: Intestine-selective anti-alpha4beta7 integrin antibody.
• Voreloxinum: RNA polymerase inhibitor; antineoplastic.
• **Zicronapiundo/Usuall (item can't be fully classified due to potential typo and placement): Antipsychotic.

This summary covers Proposed INN List 100 which includes diverse therapeutic agents, primarily targeting cancer, viral infections, metabolic disorders, and neurological conditions. Many entries are antibodies or synthetic compounds designed to interact with specific receptors or molecular targets.